What Changed
Price Move History
- Daily moves over 5%
- 30 142 sessions, April 30, 2026 to November 19, 2026
- Largest daily move
- -10.8% close of May 18, 2026
- 1-month change
- +23% closing prices, October 19, 2026 to November 19, 2026
Company Description
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases. The company focuses on pulmonary fibrosis and other interstitial lung diseases, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.
Avalyn's pipeline is built around inhaled formulations of established antifibrotic drug classes. Its lead programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. The company is developing these candidates for pulmonary fibrosis indications where treatment is directed at lung tissue affected by progressive scarring and impaired respiratory function.
The company's development model centers on targeted delivery of antifibrotic therapy through inhalation. Avalyn's research activities include clinical studies, quantitative lung imaging, patient-reported quality-of-life measures, supportive care research, and work on how patients and caregivers experience inhaled treatment. Company news has also described the use of high-resolution computed tomography imaging in AP01 research and the evaluation of AP01 delivery and supportive care experiences in pulmonary fibrosis.
Avalyn reports one operating and reportable segment: the business of developing and commercializing targeted therapies for rare lung diseases. As a clinical-stage biopharmaceutical company, its operating activities are concentrated on drug development, clinical program execution, product development, medical research, and preparations associated with potential commercialization of respiratory therapies.
Avalyn became a Nasdaq-listed public company following the closing of its initial public offering of common stock. Its public-company profile includes capital-structure matters related to its listed shares, governance updates related to its board and leadership structure, and operating updates tied to its AP01 and AP02 programs.
Stock Performance
Avalyn Pharma (AVLN) closed at $28.70 on November 19, 2026. Over the past month, the price has gained 23.0%.
AVLN Metrics & Rankings
Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Avalyn Pharma has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, conferences, clinical trial, management. View all AVLN news →
SEC Filings
Avalyn Pharma has filed 10 recent SEC filings, including 5 Form 4, 4 Form 144, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AVLN SEC filings →
Insider Radar
Insider selling at Avalyn Pharma over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Avalyn Pharma has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.
Upcoming Events
Evercore presentation
AP03 Phase 1 start
AP03 Phase 1 start planned
AURA AP02 topline data
Topline 12-month results
MIST topline data
AP01 Phase 2b results
AP03 Phase 1 results
AURA topline results
AURA topline data
AP02 Phase 2 results
Avalyn Pharma has 11 upcoming scheduled events. The next event, "Evercore presentation", is scheduled for December 1, 2026 (in 12 days). Investors can track these dates to stay informed about potential catalysts that may affect the AVLN stock price.
Short Interest History
Short interest in Avalyn Pharma (AVLN) currently stands at 2.3 million shares, down 2.2% from the previous reporting period, representing 5.7% of the float. Since May 2026, short interest has increased by 309.4%.
Days to Cover History
Days to cover for Avalyn Pharma (AVLN) currently stands at 5.3 days, down 20.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since May 2026, the figure has increased by 292.6%. Across the settlements charted above, it has ranged from 1.4 to 11.3 days.
AVLN Company Profile & Sector Positioning
Avalyn Pharma (AVLN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing AVLN often look at related companies in the same sector, including Damora Therapeutics, Inc. (DMRA), Hemab Therapeutics Holdings, Inc. (COAG), Kailera Therapeutics, Inc. (KLRA), Generate Biomedicines, Inc. (GENB), and Ascentage Pharma Group International (AAPG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AVLN's relative position within its industry.